If you've spent any time in these threads you've seen both posts. One person is down 60 lbs and calls it a miracle. Someone on the exact same drug at the exact same dose is barely down 4 lbs after six months and feels like they're broken. Both are telling the truth. GLP-1 response is a spectrum, not a switch, and understanding where you fall on it is the difference between quitting too early and troubleshooting your way to results.

Here's the actual breakdown, because "it works" is doing a lot of hiding.

The four buckets

Researchers who tracked large groups of patients on semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) sorted everyone into rough categories based on how much of their starting body weight they lost:

• Super-responders: more than 15% of body weight lost
• Moderate responders: 5–15% lost (this is most people)
• Minimal / non-responders: less than 5% lost
• Regainers: lost weight, then crept back up

The split matters. Somewhere around 10–17% of people are true non-responders — under 5% loss. Meanwhile the odds of being a super-responder depend heavily on which drug you're on. In one large analysis, super-responder rates were roughly 34% on Zepbound, 26% on Wegovy, 24% on Mounjaro, and about 10% on Ozempic. Tirzepatide (the dual-hormone drugs) pulled far more people into the top bucket than semaglutide did.

To put the top bucket in human terms: super-responders in these studies essentially reversed around 20 years of gradual weight gain in a single year. Moderate responders reversed about a decade. Non-responders barely moved the needle. Same medications.

So why the enormous gap?

It's rarely one thing. The big drivers:

Genetics. This is the frontier and the most interesting part. Carrying certain variants of the GLP1R gene (the receptor these drugs actually bind to) is linked to noticeably more weight loss — and, annoyingly, more nausea, since the two travel together. Cleveland Clinic researchers have been building a predictive "response score" around another gene, neurobeachin. And some people appear to have a form of GLP-1 resistance: their bodies make plenty of the hormone but the downstream signaling doesn't fire properly, so flooding the system with a drug version does less.

Diabetes status. People taking these drugs for type 2 diabetes tend to lose less weight than people taking them purely for obesity. Not a character flaw — a metabolic one.

Sex. On average, men lose a smaller percentage than women on the same drug.

Dose and titration. A lot of "non-responders" are actually under-dosed or were rushed/stalled during titration. Plenty of people see nothing at 0.5 mg and everything at 1.7–2.4 mg. Time on drug matters too — real response curves keep climbing past the 6-month mark.

The drug itself. As the numbers above show, the dual-agonists (tirzepatide) simply move more people into higher response tiers than semaglutide. If you've maxed out one and stalled, you're not necessarily a "non-responder" — you may be a non-responder to that specific mechanism.

The obvious-but-underrated stuff. Protein intake, resistance training to protect muscle, sleep, alcohol, and other meds all shift the outcome. GLP-1s reduce appetite; they don't override a large calorie surplus, and they don't build the muscle that keeps your metabolism up.

What to actually do with this

If you're in the minimal-response bucket, before you conclude the drug "doesn't work for you," a few honest questions: Are you at a therapeutic dose, or did titration stall? Has it actually been long enough (think months, not weeks)? Are you on semaglutide and could reasonably discuss switching to a dual-agonist with your prescriber? Is protein and resistance training in place, or are you losing muscle and calling it a plateau? Any other conditions or meds working against you?

And if you're a super-responder — the mechanism that's working for you may not be the willpower everyone congratulates you on. It's often genetics you didn't choose. Worth staying humble in the comments toward the people grinding for every pound.

The single most useful reframe: a non-response to one GLP-1 is not a verdict on your body. It's a data point about one drug, one dose, one mechanism, one moment. The people getting dramatic results and the people getting nothing are usually separated by biology and protocol details, not effort.